Ness Ziona, 5th January 2015. Vaxil Bio (TASE: VAXL), which is developing immunotherapeutic
products to treat cancer and infectious diseases, reports today that it has received approval from
Kaplan’s medical center, Rehovot, ethical (Helsinki) committee, to open up a second center at this
hospital, for its phase I/II clinical trial VAXIL-010. The study which is currently being executed at
Hadassah MC Jerusalem, evaluate the safety, immunity and clinical efficacy of ImMucin as a
treatment for patients with MUC1 positive metastatic breast cancer, in combination with their
hormone therapy.
The Principal Investigator at Kaplan MC is Dr. Noa ben-Baruch of the Department of Oncology. The study is planning to enroll up to 20 patients from which 4 have already started treatment at Hadassah MC. Vaxil is planning to start enrolling patients at Kaplan MC in the near future.
Help employers find you! Check out all the jobs and post your resume.
The Principal Investigator at Kaplan MC is Dr. Noa ben-Baruch of the Department of Oncology. The study is planning to enroll up to 20 patients from which 4 have already started treatment at Hadassah MC. Vaxil is planning to start enrolling patients at Kaplan MC in the near future.
Help employers find you! Check out all the jobs and post your resume.
